Adherence to Hydroxyurea Therapy for Pediatric Sickle Cell Anemia in Tanzania: Evidence from Bugando Medical Centre

Maria Inviolata Subira1, Emmanuela E Ambrose2,3, Eveline Konje4

  • 1School of Public Health, Catholic University of Health and Allied Sciences, Mwanza P.O. Box 1464, Tanzania.

Insights

Adherence to hydroxyurea treatment for Sickle Cell Anemia (SCA) is low in pediatric patients at Bugando Medical Centre. Caregiver education and child

Area of Science:

  • Hematology
  • Pediatric Medicine
  • Public Health

Background:

  • Hydroxyurea is crucial for managing Sickle Cell Anemia (SCA) symptoms.
  • Adherence to hydroxyurea therapy presents challenges, especially in resource-limited settings.
  • Undocumented adherence issues exist among pediatric SCA patients at Bugando Medical Centre.

Purpose of the Study:

  • To evaluate hydroxyurea adherence rates in caregivers of pediatric SCA patients at Bugando Medical Centre.
  • To identify factors associated with non-adherence to hydroxyurea treatment.

Main Methods:

  • Analytical cross-sectional study involving 172 participants.
  • Data analyzed using Stata version 15 with modified Poisson regression.
  • Associations between exposures and adherence to hydroxyurea treatment were determined.

Main Results:

  • Good adherence was observed in only 23.8% of participants; 76.2% showed moderate to poor adherence.
  • Children aged 1-10 years were more likely to have good adherence (aPR = 2.98).
  • Caregiver's education level (secondary: aPR = 1.41; college/university: aPR = 1.92) and good knowledge of hydroxyurea (aPR = 1.55) were associated with better adherence.

Conclusions:

  • Child's age and caregiver's educational level significantly influence hydroxyurea adherence in pediatric SCA.
  • Overall adherence rates remain low, necessitating targeted interventions.
  • Enhancing caregiver knowledge and awareness is vital for improving hydroxyurea adherence.

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...